Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pregnenolone for Anxiety and Depression in Veterans
NCT06188923Phase 2
Key facts
- Status
- Recruiting
- Start
- Aug 2025
- Primary completion
- Jun 2028
- Countries
- 1
- Sponsor
- VA Office of Research & Development
- Modality
- Small Molecules
- Drugs
- pregnenolone
- Conditions
- anxiety disordermajor depressive disorder (MDD)
01
Overview
Phase 2, randomised, double-blind trial in anxiety disorder and major depressive disorder (MDD) comparing Pregnenolone with Placebo (2 arms). Primary endpoint: World Health Organization Disability Assessment Schedule II at 10 weeks. Started Aug 2025; status: recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Pregnenolone
Pregnenolone flexible dosing for 8 weeks
Placebo
Placebo for 8 weeks
03
Who it enrols
Veterans with moderate to severe anxiety and depression symptoms (PHQ-ADS >= 20), excluding those with severe PTSD, bipolar disorder, schizophrenia, current suicidal ideation, or recent substance use disorders.
04
Endpoints
Primary
World Health Organization Disability Assessment Schedule II
Secondary
Patient Health Questionnaire Anxiety and Depression Scale
Brief Pain Inventory, Second Edition
Pittsburgh Sleep Quality Index
Beyond the preview
Go deeper on NCT06188923.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06188923.